ALBT_OUT_1 [2025-04-29 08:45:41 -0400] 6168 Bytes | 1661 tokens | Cum: 1661 tkns (20.76% of 8k)
==========================================================================

Captain's log, 8:45 AM on Tue Apr 29, 2025. Target in sight: Avalon GloboCare (ALBT), moving from $4.05 to $4.34. Risk: acceptable. Opportunity: unknown. We proceed to analysis.

--- COMPANY PROFILE ---
Company: Avalon GloboCare (ALBT)
IPO: 2016-02-22 (9 Years Ago)
Market Cap: $5,339,798
Shares Outstanding: 1,090,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.

Here’s a list of headlines for Avalon GloboCare:

Today 08:00AM - Avalon GloboCare Advances Proposed Merger with YOOV with Filing of Registration Statement
Apr-15-25 08:00AM - Avalon GloboCare Partners with SpecialtyHealth, Inc. to Power Police Chiefs' Fitness Challenge with KetoAir
Apr-10-25 08:00AM - Avalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China
Apr-01-25 09:00AM - Avalon GloboCare Partners with Pounds Transformation Clinics to Unveil the KetoAir BrAce 4 Impact Challenge Series
Mar-10-25 08:00AM - Avalon GloboCare and YOOV, a Leading Business AI Automation Solutions Provider, Enter into Merger Agreement
Feb-27-25 08:00AM - Fusion Fuel Appoints Luisa Ingargiola to Board of Directors
Feb-18-25 09:00AM - Avalon GloboCare Receives Notice of Allowance for Groundbreaking CAR-T and CAR-NK Cell Technology in China
Nov-21-24 09:00AM - Avalon GloboCare Regains Compliance with Nasdaq Continued Listing Requirements
Nov-18-24 09:00AM - Avalon GloboCare Launches BrAce for Impact' Affiliate Marketing Program for the KetoAir Breathalyzer Device
Oct-31-24 09:00AM - Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales
Oct-25-24 09:00AM - Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
Oct-25-24 09:00AM 08:31AM - EXCLUSIVE: Avalon GloboCare Inks MoU With Qi Diagnostics For Proposed Co-Development Of Real-Time Cannabis Breathalyzer
Oct-24-24 09:00AM - Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan
Oct-09-24 09:00AM - Avalon GloboCare to Sponsor Keto Pa-LOU-za 2024 Conference and Showcase KetoAir Breathalyzer Device
Aug-14-24 08:00AM - Avalon's Laboratory Services MSO to Launch Sales of Proprietary FDA-Registered External Male Catheter Device
Aug-14-24 08:00AM 07:30AM - EXCLUSIVE: Avalon's Lab Services MSO Poised To Commercialize FDA-Registered External Male Catheter Device
Jul-31-24 08:00AM - Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
Jul-18-24 09:00AM - Avalon GloboCare Launches Online Sales of KetoAir Breathalyzer in the U.S. at Ketoair.us
Jun-21-24 07:30AM - 7 F-Rated Penny Stocks to Avoid This June
Jun-20-24 08:30AM - Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference
Jun-04-24 11:00AM - Paramount Layoffs 2024: What to Know About the Latest PARA Job Cuts
Jun-04-24 11:00AM 08:55AM - Why Is Avalon Globocare (ALBT) Stock Down 27% Today?

Prior AI Reports for ALBT:
1. 2025-03-19 – Score: 50 – Target: 6.7500 – Highs: 6.7200 / 7.8852 / 6.49
short-term-growth-observed-despite-concerning-financial-indicators

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-11-18T14:00:00Z - Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device
B2 - 2024-10-25T13:00:00Z - Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
B3 - 2024-07-09T09:33:25Z - Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Mainz Biomed ... - Benzinga
B4 - 2024-05-24T21:00:00Z - Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report
B5 - 2024-02-28T13:24:41Z - Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
B6 - 2023-12-18T14:00:00Z - Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Avalon GloboCare (ALBT).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ALBT_OUT_3 [2025-04-29 08:45:41 -0400] 873 Bytes | 226 tokens | Cum: 1889 tkns (23.61% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/11/18/2982829/0/en/Avalon-GloboCare-Launches-BrAce-for-Impact-Affiliate-Marketing-Program-for-the-KetoAir-Breathalyzer-Device.htmlAvalon GloboCare has launched an affiliate marketing program for its KetoAir breathalyzer device, which is designed for ketogenic health monitoring. The program offers affiliates an attractive discount and commission structure to promote the device.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_5 [2025-04-29 08:45:42 -0400] 1028 Bytes | 316 tokens | Cum: 2207 tkns (27.59% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-29T12:00:00Z - Avalon GloboCare Advances Proposed Merger with YOOV with Filing of Registration Statement - Avalon G...
A2 - 2025-04-29T12:21:50Z - Avalon GloboCare Advances Proposed Merger with YOOV with Filing of Registration Statement...
A3 - 2025-04-28T22:24:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, RDUS, ALBT, BRDG on Behalf of Shareho...
A4 - 2025-04-28T22:24:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, RDUS, ALBT, BRDG on Behalf of Shareho...
A5 - 2025-04-28T22:24:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, RDUS, ALBT, BRDG on Behalf of Shareho...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ALBT_OUT_7 [2025-04-29 08:45:43 -0400] 1182 Bytes | 325 tokens | Cum: 2534 tkns (31.67% of 8k)
==========================================================================

Showing A1 (chunk 1 of 14): A1:
**Avalon GloboCare Advances Proposed Merger with YOOV with Filing of Registration Statement - Avalon Globocare (NASDAQ:ALBT)**Date: 2025-04-29Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/04/g45064247/avalon-globocare-advances-proposed-merger-with-yoov-with-filing-of-registration-statementFREEHOLD, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") ALBT, a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, and YOOV Group Holding Limited ("YOOV"), a provider of highly advanced artificial intelligence ("AI") automation solutions, jointly announced the filing with the U.S. Securities and Exchange Commission ("SEC") of a registration statement on Form S-4 in connection with the proposed Merger (as defined below).

As previo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_9 [2025-04-29 08:45:43 -0400] 1182 Bytes | 266 tokens | Cum: 2802 tkns (35.02% of 8k)
==========================================================================

Showing A1 (chunk 2 of 14): usly announced, Avalon, Nexus MergerSub Limited, a business company incorporated in the British Virgin Islands and a wholly owned subsidiary of Avalon ("Merger Sub") and YOOV, a business company incorporated in the British Virgin Islands, entered into an Agreement and Plan of Merger, dated March 7, 2025 (the "Merger Agreement"), pursuant to which Merger Sub will merge with and into YOOV, with YOOV surviving the merger (the "Surviving Corporation") and becoming a wholly owned direct subsidiary of Avalon (the "Merger"). The Merger will result in a publicly-traded company focused on empowering organizations of all sizes to optimize operations, reduce costs, and enhance service delivery through Artificial Intelligence-as-a-Service (AIaaS) solutions, specializing in intelligent business automation.

The closing of the transactions contemplated by the definitive agreement is subject to certain

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_11 [2025-04-29 08:45:44 -0400] 1182 Bytes | 259 tokens | Cum: 3063 tkns (38.29% of 8k)
==========================================================================

Showing A1 (chunk 3 of 14): conditions, including, without limitation, the approval of the stockholders of Avalon and the approval by the Nasdaq Stock Market of the listing of YOOV following the closing of the Merger.

About YOOV Group Holding Limited

YOOV is an Artificial Intelligence-as-a-Service (AIaaS) platform specializing in intelligent business automation, integrating AI, process and data into one platform to make business operations easy, efficient, and effortless. YOOV empowers businesses of all sizes to use AI without the need for extensive resources or technical expertise. By integrating AI with its no-code workflow automation platform, YOOV delivers versatile solutions tailored to meet the diverse needs of various industries. Over the years, YOOV has been growing rapidly with a strong global presence.

Beyond its core AI automation solutions, YOOV extends its offerings into financial and insurance ser

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_13 [2025-04-29 08:45:45 -0400] 1184 Bytes | 250 tokens | Cum: 3315 tkns (41.44% of 8k)
==========================================================================

Showing A1 (chunk 4 of 14): vices through its subsidiaries, YOOV Capital Limited and YOOV Insurance Services Limited. These subsidiaries leverage YOOV's commercial data insights to provide credit evaluation and insurance brokerage services, further enhancing the YOOV ecosystem and delivering added value to clients.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. ALBT is a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. Avalon is currently marketing the KetoAir™ breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAirTM is registered with the U.S. Food and Drug Administration as a Class I medical device. In addition, Avalon owns and operates commercial real estate.

No Offer or Solicitation

This communication shall not constitute an off

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_15 [2025-04-29 08:45:45 -0400] 1182 Bytes | 265 tokens | Cum: 3582 tkns (44.77% of 8k)
==========================================================================

Showing A1 (chunk 5 of 14): er to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act").

Additional Information About the Proposed Merger for Investors and Shareholders

This communication relates to the proposed merger of Avalon and YOOV (the "proposed Merger"). In connection with the proposed Merger, Avalon has filed relevant materials with the U.S. Securities and Exchange Commission (the "SEC"), including a Registration Statement on Form S-4 that cont

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_17 [2025-04-29 08:45:46 -0400] 1182 Bytes | 279 tokens | Cum: 3863 tkns (48.29% of 8k)
==========================================================================

Showing A1 (chunk 6 of 14): ains a preliminary prospectus and preliminary proxy statement of Avalon (the "proxy statement/prospectus"). This Registration Statement has not yet been declared effective and Avalon has filed or may file other documents regarding the proposed Merger with the SEC. This press release is not a substitute for the proxy statement/prospectus or for any other document that Avalon has filed or may file with the SEC in connection with the proposed Merger. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLD

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_19 [2025-04-29 08:45:47 -0400] 1182 Bytes | 272 tokens | Cum: 4137 tkns (51.71% of 8k)
==========================================================================

Showing A1 (chunk 7 of 14): ERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to Avalon's stockholders. Investors and security holders will be able to obtain these documents (when available) free of charge from the SEC's website at www.sec.gov. In addition, investors and stockholders should note that Avalon communicates with investors and the public using its website (https://www.avalon-globocare.com), the investor relations website (https://www.avalon-globocare.com/investors) where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Avalon with the SEC, and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed Merger.

Participants in the S

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_21 [2025-04-29 08:45:47 -0400] 1182 Bytes | 266 tokens | Cum: 4405 tkns (55.06% of 8k)
==========================================================================

Showing A1 (chunk 8 of 14): olicitation

Avalon, YOOV and their respective directors and executive officers and other members of management and employees and certain of their respective significant stockholders may be deemed to be participants in the solicitation of proxies from Avalon and YOOV stockholders in respect of the proposed Merger. Information about Avalon's directors and executive officers is available in Avalon's Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 31, 2025. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, has been and will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the Proposed Merger when they become available. Investo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_23 [2025-04-29 08:45:48 -0400] 1182 Bytes | 267 tokens | Cum: 4674 tkns (58.43% of 8k)
==========================================================================

Showing A1 (chunk 9 of 14): rs should read the definitive proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC and Avalon as indicated above.

This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. These statements are only predictions. Avalon and YOOV have based these forward-looking statements largely on their then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forw

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_25 [2025-04-29 08:45:49 -0400] 1183 Bytes | 265 tokens | Cum: 4941 tkns (61.76% of 8k)
==========================================================================

Showing A1 (chunk 10 of 14): ard-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond each of Avalon's and YOOV's control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the risk that the conditions to the closing or consummation of the proposed Merger are not satisfied, including the failure to obtain stockholder approval for the proposed Merger; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Avalon and YOOV to consummate the transactions contemplated by the proposed Merger; (iii) risks related to Avalon's and YOOV's ability to correctly estimate their respective operating expenses and expenses associated with the proposed Merger, as applicable, as well as uncert

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_27 [2025-04-29 08:45:50 -0400] 1151 Bytes | 312 tokens | Cum: 5255 tkns (65.69% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-29 8-K Item 7.01 Regulation FD Disclosure.

On April 29, 2025, Avalon GloboCare Corp. (Avalon) and YOOV Group Holding Limited (YOOV) issued a joint press release announcing the filing of a Registration Statement on Form S-4 in connection with the proposed merger of Avalon and YOOV (the...

S2 - 2025-04-15 8-K Item 7.01. Regulation FD Disclosure.

On April 15, 2025, Avalon GloboCare Corp. (the Company) issued a press release announcing that it has partnered with SpecialtyHealth, Inc. to power the BrAce 4 Impact Challenge, a police chiefs fitness challenge, with the Companys KetoAir br...

S3 - 2025-04-10 8-K Item 7.01. Regulation FD Disclosure.

On April 10, 2025, Avalon GloboCare Corp., a Delaware corporation (the Company), issued a press release announcing an update regarding its patent right and Certificate of Invention for its CAR-T and CAR-NK cell technology.

The press releas...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALBT_OUT_29 [2025-04-29 08:45:50 -0400] 1181 Bytes | 292 tokens | Cum: 5549 tkns (69.36% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7.01 Regulation FD Disclosure.

On April 29, 2025, Avalon GloboCare Corp. (Avalon) and YOOV Group Holding Limited (YOOV) issued a joint press release announcing the filing of a Registration Statement on Form S-4 in connection with the proposed merger of Avalon and YOOV (the Merger). The press release and the information set forth therein shall not be deemed to be filed for purposes of Section 18 of the Exchange Act of 1934, as amended (the Exchange Act), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act.

Additional Information about the Proposed Merger and Where to Find It

This Current Report on Form 8-K does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_31 [2025-04-29 08:45:51 -0400] 1181 Bytes | 281 tokens | Cum: 5832 tkns (72.90% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): a solicitation of any vote or approval. This Current Report on Form 8-K relates to the proposed Merger of Avalon and YOOV. In connection with the proposed Merger, Avalon has filed a Registration Statement on Form S-4, which includes a preliminary prospectus and preliminary proxy statement of Avalon (the proxy statement/prospectus). This registration statement has not yet been declared effective and Avalon has filed or may file other documents regarding the proposed Merger with the SEC. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_33 [2025-04-29 08:45:52 -0400] 1181 Bytes | 270 tokens | Cum: 6104 tkns (76.30% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED MERGER. A definitive proxy statement/prospectus will be sent to Avalons stockholders. Investors and security holders will be able to obtain these documents (when available) free of charge from the SECs website at www.sec.gov. In addition, investors and stockholders should note that Avalon communicates with investors and the public using its website (https://www.avalon-globocare.com/), the investor relations website (https://www.avalon-globocare.com/investors) where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Avalon with the SEC, and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed Merger.

Participants in the Solicitation

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_35 [2025-04-29 08:45:52 -0400] 1181 Bytes | 262 tokens | Cum: 6368 tkns (79.60% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6):

Avalon, YOOV and their respective directors and executive officers and other members of management and employees and certain of their respective significant stockholders may be deemed to be participants in the solicitation of proxies from Avalon and YOOV stockholders in respect of the proposed Merger. Information about Avalons directors and executive officers is available in Avalons Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 31, 2025 and subsequent filings made with the SEC. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed Merger when they become ava

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_37 [2025-04-29 08:45:53 -0400] 1181 Bytes | 257 tokens | Cum: 6627 tkns (82.84% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): ilable. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC and Avalon as indicated above.

No Offer or Solicitation

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Forward-Looking Statements

This Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 contain forward-looking statements based upon A

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_39 [2025-04-29 08:45:54 -0400] 790 Bytes | 184 tokens | Cum: 6813 tkns (85.16% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): valons and YOOVs current expectations. This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as believe, may, will, estimate, continue, anticipate, intend, could, should, would, project, plan, expect, goal, seek, future, likely or the negative or plural of these words or similar expressions. These statements are only predictions. Avalon and YOOV have based these ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ALBT_OUT_41 [2025-04-29 08:46:01 -0400] 5853 Bytes | 1561 tokens | Cum: 8378 tkns (104.72% of 8k)
==========================================================================

This is our set of metrics for Avalon GloboCare.
Please analyze the numbers.

+--------------------+----------------------+------------------------+----------------------+
| Volume: 244,835 | Perf Month: -23.87% | Option/Short: No / Yes | Sales Y/Y TTM: 6.19% |
+--------------------+----------------------+------------------------+----------------------+
| Avg Volume: 84.28K | Perf Quarter: 19.47% | Short Float: 5.01% | ROE: -109.23% |
+--------------------+----------------------+------------------------+----------------------+
| Rel Volume: 3.07 | Index: - | Short Ratio: 0.38 | ROI: -111.27% |
+--------------------+----------------------+------------------------+----------------------+
| RSI (14): 47.45 | Market Cap: 6.69M | Short Interest: 0.03M | Sales Surprise: - |
+--------------------+----------------------+------------------------+----------------------+
| ATR (14): 0.62 | Shs Outstand: 1.44M | Beta: -0.01 | EPS Surprise: - |
+--------------------+----------------------+------------------------+----------------------+
| SMA20: 3.10% | Shs Float: 0.64M | Sales Q/Q: 7.61% | P/E: - |
+--------------------+----------------------+------------------------+----------------------+
| SMA50: -23.59% | Inst Own: 1.01% | Sales past 5Y: -2.57% | Earnings: - |
+--------------------+----------------------+------------------------+----------------------+
| SMA200: -4.09% | Insider Own: 61.27% | Employees: 5 | |
+--------------------+----------------------+------------------------+----------------------+
| Perf Week: 25.39% | Insider Trans: 0.00% | Debt/Eq: 1.10 | |
+--------------------+----------------------+------------------------+----------------------+

The next section covers any insider trading by Avalon GloboCare officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 345159, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -1679200.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.05
Average Volume: 74510.3
30-Day High: 4.88
30-Day Low: 3.2

[Detailed Financials: Q3 2024]
- Total Assets: $19,550,633.00
- Total Liabilities: $14,149,229.00
- Total Equity: $5,401,404.00
- Current Assets: $1,396,821.00
- Current Liabilities: $12,332,173.00

[Income Statement: Q3 2024]
- Revenue: $345,159.00
- Net Income: $-1,679,200.00
- Gross Profit: N/A
- Operating Income: $-1,269,961.00
- Earnings Per Share (EPS): -1.82

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $823,625.00

[Detailed Financials: Q2 2024]
- Total Assets: $19,515,972.00
- Total Liabilities: $15,099,019.00
- Total Equity: $4,416,953.00
- Current Assets: $712,881.00
- Current Liabilities: $8,593,186.00

[Income Statement: Q2 2024]
- Revenue: $327,887.00
- Net Income: $-2,132,026.00
- Gross Profit: N/A
- Operating Income: $-1,504,363.00
- Earnings Per Share (EPS): -0.19

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-85,823.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Avalon GloboCare (ALBT).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Avalon GloboCare.

2) MARKET_SCORE[]
This conversation was initiated because ALBT is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ALBT.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ALBT could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ALBT to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Avalon GloboCare.

11) ETHICAL_RATING[]
Rate Avalon GloboCare’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Avalon GloboCare.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ALBT_IN_43 [2025-04-29 08:46:01 -0400] 126 Bytes | 29 tokens | Cum: 8604 tkns (107.55% of 8k)
==========================================================================

====================================
[2025-04-29 08:46:01] # Analysis Completed
Elapsed Time: 21.28 seconds